focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

Thu, 04th Apr 2024 17:24

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Artemis Resources Ltd - gold, copper and lithium-focused exploration company with projects in Western Australia - Updates on Karratha gold project exploration programme in West Pilbara, Western Australia. Says Lulu Creek will be drill tested in the third quarter of 2024. Adds that programme of works is submitted and approved, with heritage clearance application underway.

----------

Develop North PLC - investor in residential and commercial property sector - Starts share buyback programme of up to GBP500,000. The programme is set to end on June 30 and could be terminated earlier.

----------

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Raises GBP51,670 via issuing 5.2 million retail offer shares at a price of 1 pence each. Applies to the London Stock Exchange for the admission of a total of 152.5 million new shares to trading on AIM, comprising of 79.4 million placing shares, 5.6 million subscription shares and 62.3 million initial consideration shares

----------

Genflow Biosciences PLC - London-based biotechnology company focused on longevity - Raises GBP715,000 via its broker Capital Plus Partners by placing 57.2 million shares. Chief Executive Officer Eric Leire invested GBP50,000 personally in the placing, the company says.

----------

Insig AI PLC - London-based data science and machine learning firm - Agrees to a GBP250,000 equity funding facility with Executive Chair Richard Bernstein, which will allow him to subscribe for up to around 1.3 million new shares at 20 pence per share until the end of August.

----------

Northcoders Group PLC - Manchester-based software coding training provider - Launches part-time business-to-costumer software development bootcamp that aims to make careers in tech more accessible. The virtual course will start in mid-July and has been created due to demand for alternative structures, Northcoders says. Chief Executive Officer Chris Hill says: "Not only is this in line with the group's strategy to address the nation's widening digital skills, but it embodies our commitment to inclusivity and flexibility, ensuring that anyone who is interested in the opportunity to work in the ever-growing UK technology market can pursue their ambitions, regardless of their schedule or background."

----------

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company - Raises GBP1.2 million via issuing 11.7 million fundraising shares at the placing price of 10p per share.

----------

Schroder BSC Social Impact Trust PLC - investment firm focused on positive social impact as well as long-term capital growth and income - Announces GBP5 million commitment to Savills IM Simplify Affordable Homes Ltd Partnership, which will lie within Schroder's High Impact Housing asset class allocation. "The UK continues to face a housing crisis with an acute lack of social and affordable housing and this fund will deliver homes for lower income households and people currently in need of social housing in areas in most need. The SAH management team have a strong track record, with over 30 years' expertise and deep sector knowledge with long standing housing association relationship. We believe they are well-placed to deliver high quality financial and impact returns through providing affordable housing at-scale," says Jeremy Rogers, chief investment officer of Big Society Capital, portfolio manager of Schroder BSC.

----------

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
27 Jul 2018 13:14

Friday broker round-up

(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.

Read more
26 Jul 2018 12:54

Evgen Pharma Expects Final Results From Clinical Trials At End Of Year

LONDON (Alliance News) - Evgen Pharma PLC said Thursday it expects to receive the final read-out from two clinical trials by the end of 2018.The drug development company said at its annual

Read more
25 Jul 2018 14:48

Evgen concludes patient recruitment in STEM breast cancer trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer, it announced on Wednesday.

Read more
25 Jul 2018 13:57

Wednesday broker round-up

(Sharecast News) - Unite Group: Numis downgrades to hold with a target price of 900p.

Read more
25 Jul 2018 13:31

Evgen Pharma Metastatic Breast Cancer Trial Ends Patient Recruitment

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it has concluded its patient recruitment for its STEM Phase IIa trial of SFX-01 in metastatic breast cancer.Following the favourable

Read more
19 Jul 2018 16:21

UK Shareholder Meetings Calendar - Next 7 Days

Friday 20 JulyHomeserveKCOM GroupMonday 23 JulyEthernity Energy 24

Read more
13 Jun 2018 10:46

Evgen Pharma Annual Loss Narrows As It Continues Phase II Trials

LONDON (Alliance News) - Clinical drug development company Evgen Pharma PLC said Wednesday its annual loss narrowed in line with expectations.Evgen, which focuses on cancer and neurological

Read more
11 Jun 2018 11:33

Evgen STEM Interim Trial Result Show "Signs Of Anti-Tumour Activity"

LONDON (Alliance News) - Evgen Pharma PLC said Monday its STEM trial showed "early signs of anti-tumour activity" in breast cancer patients.STEM is the company's study of in a

Read more
2 May 2018 11:15

Evgen Pharma Gets European Patent For Sulforaphane Stablising Method

LONDON (Alliance News) - Drug development company Evgen Pharma said Wednesday that it has secured a European patent recognising its intellectual property for a method of stabilising sulforaphane,

Read more
20 Mar 2018 13:56

Evgen Pharma Begins Research Partnership With Imperial College London

LONDON (Alliance News) - Drug development company Evgen Pharma PLC has started a new research collaboration with Imperial College London focusing on SFX-01, the company's

Read more
13 Feb 2017 08:21

Evgen Pharma signs service agreement with drug development corsortium

(ShareCast News) - AIM-listed Evgen Pharma has signed a services agreement with a consortium of Cheshire-based drug developments firms for its sulforaphane product. APT Trans, the consortium of drug developers based in the Biohub at Alderley Park, which comprises of Aptus Clinical, Apconix and Seda

Read more
17 Jan 2017 12:35

Richard Moulson to join Evgen Pharma as CFO

(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson as its chief financial officer on Tuesday. The AIM-traded firm said Moulson was joining immediately as CFO-designate for a handover period to 28 Febru

Read more
11 Jan 2017 09:23

Evgen Pharma receives go ahead for haemorrhage drug trial

(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board (DSMB) for its Phase II double-blind placebo-controlled SAS trial

Read more
11 Jan 2017 09:17

Evgen Pharma Gets Positive Review For SFX-01 Phase II Study

Read more
17 Aug 2016 10:49

Evgen Pharma receives approval for breast cancer study

(ShareCast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that it has received a Clinical Trial Approval from the UK's regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer. The AIM-traded firm said patient recruitment w

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.